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therapy is associated with higher basal
insulin doses
Claudia Boucher-Berry1* , Elaine A. Parton2 and Ramin Alemzadeh3
Abstract
Background: While higher total daily dose (TDD) of insulin has been associated with excess weight gain on insulin
pump therapy, the role of higher total basal dose (TBD) of insulin on weight gain has not been studied. We
evaluated the impact of higher TBD on weight gain in relationship to glycosylated hemoglobin (HbA1c),
hypoglycemic episodes, and change in body mass index (BMI) z score in a group of pediatric patients with type 1
diabetes mellitus (T1DM).
Methods: One-year data from 91 (54 Female/37 Male) patients (2.3–17.8 years of age), transitioned from basal-bolus
regimen to insulin pump therapy were reviewed. Patients were divided into two groups based on changes in BMI z
score: Group 1 (no change or decrease) and Group 2 (increase).
Results: Thirty-three patients in Group 1 and 58 patients in Group 2. The two groups had similar TDD (0.9 ± 0.2 vs.
0.8 ± 0.2 U/kg/day), however Group 1 had a higher bolus: basal insulin ratio (1.8 ± 0.6 vs. 1.5 ± 0.6, p < 0.05). While
Groups 1 and 2 had similar HbA1c values (7.7 ± 0.7 vs. 7.70 ± 0.6 %; p = 0.79) and activity levels (2.2 ± 0.6 vs. 2.2 ± 0.7;
p = 0.15), Group 2 had higher rates of hypoglycemic episodes (1.0 ± 0.4 vs. 1.5 ± 0.9, p < 0.01).
Conclusion: Excess weight gain was associated with lower bolus to basal insulin ratios independent of glycemic
control and activity level. Evaluation of bolus and basal insulin doses during insulin therapy is warranted in order to
avoid excess weight gain.
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Background
Type 1 Diabetes (T1DM) is an autoimmune disease
characterized by pancreatic beta cell destruction leading
to decreased insulin secretion [1]. It is the third most
prevalent chronic disease of childhood in the US [2, 3],
with an estimated prevalence of 1.54 cases/1000 youth
[4]. The mainstay of treatment for Type 1 Diabetes is
exogenous insulin using a combination of basal and
bolus insulin [5–7]. The basal and bolus insulins are
responsible for two separate elements of glycemic con-
trol. Basal insulin is responsible for the maintenance of
euglycemia in the absence of food. Bolus insulin is
responsible for metabolizing dietary carbohydrates and
for reducing absolute values in blood glucose when in a
hyperglycemic state [8].
A well-known disadvantage of exogenous insulin ther-
apy is weight gain associated with insulin administration
[9]. Previous studies have shown that using basal-bolus
insulin tends to produce less weight gain compared to
intermediate acting insulin such as NPH [10, 11].
However, there is still significant weight gain associated
with basal-bolus insulin and this can be distressing,
especially for adolescents attempting to achieve optimal
control. Multiple studies have evaluated the relationship
between daily insulin dose and weight gain by examining
the factors that play a role in this complex relationship.
The United Kingdom Prospective Diabetes Study (UKPDS)
showed that total weight gain was associated with total
exogenous insulin dose [12]. Patients in the intensive treat-
ment arm of the Diabetes Control and Complications trial
* Correspondence: claudiab@uic.edu
1Department of Pediatrics, Section of Pediatric Endocrinology, Children’s
Hospital of Illinois, University of Illinois at Chicago, 840 S. Wood Street, M/C
856, 330 CSN, Chicago, IL 60612, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Boucher-Berry et al. Journal of Diabetes & Metabolic Disorders  (2016) 15:47 
DOI 10.1186/s40200-016-0271-5
(DCCT) showed greater weight gain and a higher average
increase in BMI than those that received conventional
diabetes treatment [13, 14]. The intensive treatment group
gained an average of 3.3 kg compared with 1.2 kg in the
conventional group. After 5 years, the increase in BMI
remained significantly greater in the intensive group and
the differences in weight were still noted 9 years after
DCCT [13, 15]. Holl et.al went further and postulated that
along with high insulin doses, other factors that predispose
to weight gain are initiation of intensified insulin therapy,
tight metabolic control and female gender [16]. Holl also
suggested that the excessive weight gain may in fact be a
direct result of the flexibility of the basal-bolus regimen-
allowing for high dietary carbohydrate intake [16].
Looking at the total dose of insulin in comparison to
weight gain is only half of the picture. Since the total
daily dose (TDD) of insulin is comprised of the basal
and the bolus insulin, it is important to elucidate the
necessary ratio of basal to bolus insulin that will lead to
glycemic control without excessive gains in weight. The
standard modality for calculation of basal and bolus
insulin dosages uses the basal dose as 50% for the total
daily insulin dose [17–20]. The purpose of this study
was to assess the relationship between basal and bolus
insulin dosages and weight gain. The goal is to answer
the question- is it the basal insulin dose or the bolus
insulin dose that contributes most to the weight gain
associated with insulin therapy.
Methods
Study subjects
Data from ninety-one children and adolescents (ages 2.3
– 17.8 years) were collected. All patients were cared for
at the Children’s Hospital of Wisconsin Diabetes Center.
The participants were converted from basal bolus ther-
apy using injections [once daily glargine and a premeal
rapid acting (Aspart) analogue]) to insulin pump ther-
apy. Prior to transitioning to the insulin pump, the fam-
ilies were evaluated by the Diabetes team to assess their
ability to successfully transition to insulin pump therapy.
Insulin pump education also included insulin adjustment
techniques for management of persistent hyperglycemia
or hypoglycemia associated with illness and/or exercise.
Study design
For each patient data were collected at the beginning of the
transition period and then 1 year later. Patients were eva-
luated at quarterly Diabetes clinic visits and the following
data were collected: HbA1c, height, weight, BMI, and
Tanner stage. Participants were evaluated by their primary
endocrinologist for Tanner staging. Total daily insulin dos-
age per kilogram was calculated and insulin adjustments
were made at the discretion of the primary endocrinologist
or nurse practitioner to improve Diabetes control.
The average fasting glucose from self-monitored blood
glucose (SMBG) documentation was calculated. At every
visit, the number and severity of hypoglycemic episodes
in the preceding 3 months was determined. The number
of severe hypoglycemic episodes was defined as blood
glucose less than 50 mg/dl ((<2.8 mmol/l) associated
with unconsciousness with or without seizure (expressed
as events per 100 patient-years). The frequency of mild
to moderate hypoglycemia defined as blood glucose less
than 70 mg/dl (<3.9 mmol/l) (with or without behavioral
impairment) was expressed as hypoglycemic episodes
per week. Hypoglycemia data were recorded at each visit
for the preceding 3 months.
Families were routinely asked to report the number of
visits to the emergency room and hospital admissions
associated with Diabetes that occurred in between out-
patient visits. Finally, the families were asked to fill out an
activity survey [21] to appropriately describe their child’s
activity level. Sedentary activity or a level of “1” was
defined as walking/running less than half a mile per day
and spending most of their time sitting or watching televi-
sion. A level of “2” was assigned to anyone who walks
between half a mile and 1.5 miles per day and/or spends
comparatively more time in active play than reading or
watching television. Finally, a level of “3” was assigned to
anyone who identified themselves as being active- in-
volved in any exercise program 2–3 times per week. These
activity surveys were completed at each visit.
This study was approved by the Institutional Review
Board (IRB) of Children’s Hospital of Wisconsin. The IRB
approval was obtained for the retrospective review of pa-
tients’ clinical charts and therefore, informed consent was
not required. The details that might disclose the identity
of the subjects under chart review were omitted.
Nutritional assessment
All patients and their families were already using carbohy-
drate counting at baseline. Each subject and his/her family
received nutrition and meal planning recommendations
and education on the application of carbohydrate counting
to flexible insulin regimen, based on established guidelines
[22]. Food labels, exchange lists, food models, and restaur-
ant reference guides were used as educational tools. Each
patient was evaluated by a nutritionist at quarterly clinic
visits. A 24-h dietary recall with assessment of carbohydrate
counting skills was performed at each clinic visit. If any
issues arose regarding accuracy of implementation of these
guidelines, they were addressed at the clinic visit or on a
separately scheduled visit with the nutritionist.
Insulin dosage calculations and HbA1c determination
Implementation of insulin pump therapy
Before the initiation of pump therapy, all patients and
families were instructed in the mechanics of pump use
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and wore a demonstrator pump with saline for 3 days.
The patient and the family chose the pump brand
[MiniMed (Northridge, CA) and Animas (Westchester,
PA)]. Patients and families were instructed of risks of
pump use, including catheter-site infection, hypergly-
cemia, hypoglycemia, ketosis, and diabetic ketoacidosis,
and potential mechanical problems (i.e., kinked infusion
sets, air bubbles, and dislodged tubing), which could
interfere with insulin delivery.
On the day prior to pump placement, all patients
discontinued their basal insulin the night before and
used correction doses of Lispro insulin every 4 h until
the morning of pump start. The new TDD was calcu-
lated as 75 % of previous TDD (Lispro + basal insulin
regimen). Lispro insulin was used in all pumps. Fifty
percent of daily dose was used for bolus dosing, and the
remainder was used for basal rates. During the first
2 weeks of pump therapy, patients were instructed to
perform frequent blood glucose (BG) monitoring (almost
every 2 h, including preprandial, postprandial, and
overnight levels). Most patients were started on 2 to 3
basal rates and correction doses were continued from
the previous insulin regimen. All patients had daily
phone contact with a diabetes nurse educator for 7 to
14 days followed by fax or phone contact (2 to 3 times/
week) for at least 1 to 2 months.
The HbA1c was determined using the Bayer DCA
(Bayer Diagnostics Inc, Tarrytown, NY) 2000 instrument,
with a non-diabetic range of 4.5 to 5.7 %.
Statistical analysis
The patients were stratified by BMI and BMI z-score.
The patients were then divided into two groups; (1) pa-
tients whose BMI z-score were less than or the same as
the initial BMI z-score from the start of the study and
(2) patients whose BMI z-score increased over the last
year. The two groups were compared based on their
demographics, anthropometrics, pubertal status, insulin
dosages and Diabetes control. Calculations were done to
assess certain parameters at the beginning and the end
of the study. These calculations included; 1) the total in-
sulin dose per kilogram of body weight, 2) basal insulin
dose per kilogram of body weight, 3) bolus insulin dose
per kg of body weight, 4) the percent of total insulin
given as basal and 5) the percent of total insulin given as
bolus.
Baseline characteristics were compared with t-test and
X2 analyses. The HbA1c data were analyzed using paired
t-test and 1 way analysis of variance. The reported values
represent the mean ± standard deviation.
Results
Table 1 summarizes the general characteristics of both
groups. There were 33 patients whose BMI z-score had
decreased or remained the same (Group 1) and 58
patients whose BMI z-score increased (Group 2) over
the course of a year. The average baseline age was
11.9 years with no significant difference in number of
female patients between the two groups. Although the
subjects in Group 2 were older than the subjects in
Group 1 (12.6 ± 3.6 vs. 10.7 ± 4.2), the duration of
Diabetes was similar between the two groups (4.0 ± 2.8
vs. 3.9 ± 2.6, respectively). Pubertal development, as
assessed by Tanner staging, was similar between the two
groups at both points in the study.
Table 2 summarizes the insulin doses as associated
with weight and Diabetes control. The “pre” measure-
ments represent the baseline calculations at the start of
the study. The “post” measurements represent the calcu-
lations performed 1 year after transition to the insulin
pump. Data that were collected and are summarized in
Table 2 include, BMI z-score,, TDD of insulin, the
percentage of the total daily dose that was represented
by the basal insulin, bolus/basal insulin ratios, HbA1c
fasting blood glucose (FBG), frequency of hypoglycemic
episodes over a 2 week period and the activity level.
Although the participants in Group 1 had a higher BMI
z-score at the beginning of the study, the difference was
not found to be significant when compared to the BMI
z-score of Group 2. However, after 1 year of pump ther-
apy, the subjects in Group 2 had a significantly higher
BMI z-score than the subjects in Group 1 (0.85 ± 0.7 vs.
0.69 ± 0.8). In addition, the ratio of BMI z-score for each
group before the study and at 1 year suggests that the
increase in BMI z-score for Group 2 was more significant
than the decrease of BMI z-score in Group 1. The increase
in BMI z-score was not associated with any change in
activity level- as the two groups reported similar activity
levels at the beginning and at the end of the study.
Both groups were well-matched at the start of insulin
pump therapy in regards to their total daily insulin doses.
Although the TDD at the end of the year remained
the same between the two groups, Group 2 had a
significantly higher percentage of basal insulin than










11.9 ± 3.9 10.7 ± 4.2 12.6 ± 3.6 <0.05
% Female 59.3 % 60.6 % 58.6 % NS
DM duration
(years)
3.9 ± 2.6 3.9 ± 2.6 4 ± 2.8 NS
Pre Tanner
staging
2.4 ± 1.3 2.2 ± 1.4 2.5 ± 1.3 NS
Post Tanner
staging
2.9 ± 1.5 2.5 ± 1.7 3.1 ± 1.4 NS
Data are mean ± SD. Pre-Tanner staging describes the pubertal level at
baseline. Post Tanner staging is the pubertal level after one year
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Group 1. In concordance with this, the ratio of bolus to
basal insulin at the end of the study was lower in Group 2
than in Group 1 (1.5 ± 0.63 vs 1.8 ± 0.6; p < 0.05).
Overall Diabetes control, as defined by HbA1c, were
similar between the two groups at the beginning and the
end of the year. However, the subjects in Group 2
displayed a lower average HbA1c after 1 year of insulin
pump therapy and this was reflected in a decrease in
average HbA1c for the entire cohort. Although there
was a significant drop in HbA1c for Group 2 from base-
line, there was no difference in fasting blood glucose in
either group. Finally, at the beginning of the study, the
subjects in Group 2 reported significantly more frequent
episodes of hypoglycemia than the subjects in Group
1 (1.99 ± 0.86 vs. 1.48 ± 0.75). After 1 year, the average
number of episodes of hypoglycemia reported by sub-
jects in Group 2 had decreased significantly, but still
remained higher than those reported in Group 1
(1.53 ± 0.9 vs 1.0 ± 0.4).
Table 3 displays the difference in anthropometrics,
activity level, insulin requirements and Diabetes control
between male and female participants. There was no
significant difference in BMI z-score between the sexes.
Both groups had similar TDD, percentage of basal
insulin and bolus to basal ratios. They both also demon-
strated an improvement in HbA1c and in FBG. However,
females overall reported a significantly higher number of
hypoglycemic episodes as compared to males. At the
end of the study, both sexes reported an improvement in
the number of hypoglycemic episodes, however, the
number in female patients remained higher than that
reported by the males.
Discussion
In our study, we observed that higher basal doses of
insulin in patients treated on an insulin pump regimen
can result in significant weight gain. The patients in the
study who had a lower bolus:basal ratio experienced an
increase in their BMI z-score over 1 year. Previous
studies have looked at the overall impact of insulin on
weight gain [12, 13, 16, 23] and have shown that inten-
sive insulin therapy is associated with excess weight gain.
Instead of looking at the insulin dose as a whole, we
chose to investigate the ratio of bolus to basal insulin.
Although the total insulin doses per kilogram of body
weight remained the same between the two groups over
a year duration, the participants in Group 2 saw an
increase in their BMI z-score, while the participants in
Group 1 experienced no change or saw a decrease in
their BMI z-score. The group that experienced the
weight gain had a significantly higher basal percentage
and a lower bolus to basal ratio than the other cohort.
This suggests that the basal insulin is more of a con-
tributor to the weight gain than the total insulin dose.
Table 2 Clinical characteristics of Patients before and 1 year after transition to insulin pump
Characteristics All Patients (N = 91) Group 1 (N = 33) Group 2 (N = 58) P value
Pre-BMI z-score 0.6 ± 0.9 1.01 ± 0.7 0.38 ± 0.85 <0.001
Post-BMI z-score 0.80 ± 0.7 0.69 ± 0.8 0.85 ± 0.7 <0.001
Pre-Post BMI z-score 0.79 ± 0.72 -0.31 ± 0.23 0.47 ± 0.43 <0.001
Pre-TDD (U/kg) 0.9 ± 0.2 0.8 ± 0.2 0.9 ± 0.2 NS
Post- TDD (U/kg) 0.9 ± 0.2 0.8 ± 0.2 0.9 ± 0.2 NS
Pre % Basal 43.9 ± 11.6 43.5 ± 12.8 44.3 ± 10.9 NS
Post % Basal 40.7 ± 9.2 36.9 ± 7.6 42.8 ± 9.3 <0.05
Pre-bolus:basal 1.4 ± 0.7 1.5 ± 0.8 1.4 ± 0.7 NS
Post-bolus:basal 1.6 ± 0.7 1.8 ± 0.6 1.5 ± 0.63 <0.05
Pre- HbA1c 8.1 ± 0.9 7.8 ± 0.9 8.3 ± 0.8 <0.01
Post- HbA1c 7.7 ± 0.7a 7.7 ± 0.7 7.7 ± 0.6a NS
Pre-FBG 182.3 ± 45.3 179.8 ± 39.9 183.2 ± 48.8 NS
Post-FBG 163.3 ± 32.4 162.5 ± 33.7 163.4 ± 31.7 NS
Pre-hypo/2 week 1.81 + 0.85 1.48 ± 0.75 1.99 ± 0.86 <0.01
Post-hypo/2 week 1.35 + 0.85b 1.0 ± 0.4a 1.53 ± 0.9a <0.01
Pre-Activity Level 2.0 + 0.66 2.0 + 0.63 2.0 + 0.68 NS
Post-Activity Level 2.2 + 0.69 2.2 + 0.60 2.2 + 0.74 NS
Data are mean ± SD. Total daily dose (TDD), fasting blood glucose (FBG). “Pre” values represent baseline data collected at the beginning of the study per group.
“Post” values represent data collected after one year of insulin pump therapy
p value, comparison between Group 1 vs. Group 2
ap < 0.01, Comparison between pre and post characteristics
bp < 0.001, Comparison between pre and post characteristics
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Multiple studies have been done to investigate the rela-
tionship between insulin and weight gain. One mechanism
by which basal insulin can lead to increased weight gain is
through increased anabolic activity. Insulin acts as an ana-
bolic hormone which reduces lipolysis and protein catabol-
ism and promotes lipogenesis and protein formation.
Studies in humans and mice have postulated that the over
replacement of insulin in patients with Diabetes produces a
general anabolic effect that leads to increased fat accumula-
tion and weight gain [12, 24]. Liu et al explained that it is
the physiological fluctuations of insulin which play a critical
role in the balance between energy storage and energy
consumption. When these fluctuations are disrupted and
exposure to insulin becomes continuous- a situation that is
synonymous with elevated basal insulin levels- the body
balance moves toward energy storage. This leads to a clus-
ter of ectopic fat accumulation and insulin resistance [24].
Another possibility is that the increased basal insulin
may result in experienced or perceived hypoglycemia.
Increased appetite is an early, involuntary and adaptive
response to low blood glucose [25]. These patients may
inadvertently be feeding the basal insulin in order to attain
euglycemia. In this study, the cohort that gained weight
did report more frequent episodes of hypoglycemia than
their counterparts. Therefore it is conceivable that the
increased insulin is driving the hypoglycemia which is
resulting in over eating and excessive caloric intake.
It is important to analyze the ratio of basal to bolus
insulin at each clinical visit. The current recommenda-
tion is that the basal insulin should be 50% of the total
daily dose [17–20]. King et.al, evaluated pump treated
patients with Type 1 Diabetes and recommended the
basal dose to be calculated as no more than 40 % of the
TDD [26]. However in their study, Kuroda et.al, recom-
mended that the basal insulin dose not exceed 30 % of
the total daily dose [27]. Our patients were able to main-
tain good glycemic control with limited weight gain at a
basal percentage of 37 %. This suggests that even the
40 % may be an overestimation of what is needed.
Interestingly, Kuroda’s study was performed using pa-
tients in the hospital setting on a strict diabetic diet,
while our study was performed on an outpatient popula-
tion. Therefore, it is possible to limit the basal insulin
and still obtain optimal glycemic control even when the
patient is not in a structured environment.
In our population, increasing the amount of basal insulin
had the beneficial effect of improving the hemoglobin A1c-
but the detrimental effect of increased weight gain. It has
been shown that improving Diabetes control decreases the
rate of microvascular and macrovascular complications
[15]. However, this weight gain can lead to worsening of
the cardiovascular risk factors [28]. In the pediatric popula-
tion, early development of cardiovascular risk factors can
progress into development of atherosclerosis as an adult
[29–31]. Since cardiovascular disease is the leading cause of
death in patients with T1DM [32, 33], it is likely that short
term improvement in Diabetes control may lead to long
term cardiovascular morbidity and mortality. This further
stresses the importance of limiting the basal insulin to help
limit the weight gain and the negative consequences associ-
ated with weight gain.
By reducing the basal insulin whether through the basal
rates in the pump or by reducing the dose of long-acting
insulin, it is possible to improve the Diabetes control and
minimize weight gain. This goes against the belief that
strict Diabetes control will lead to weight gain and may
have implications in the management of Type 1 Diabetes,
especially in adolescents who are weight-conscious.
Conclusion
This study was a pilot study designed to look at the
relationship between basal and bolus insulin doses
with weight gain. Further studies need to be done to
evaluate the long term relationship. Our results sug-
gest that keeping the percentage of basal insulin
below 40% and encouraging the patient to bolus more
frequently may lead to less weight gain with improved
Diabetes control.
Table 3 Clinical Comparisons between male and female
Subjects
Characteristics Male (N = 37) Female (N = 54) P-value
Mean age (years) 11.8 ± 4.0 11.9 ± 3.9 NS
DM duration (years) 4.5 ± 2.6 3.7 ± 2.7 NS
Pre-BMI z-score 0.66 ± 0.88 0.58 ± 0.85 NS
Post-BMI z-score 0.87 ± 0.71 0.74 ± 0.73 NS
Pre-Activity Level 2.0 + 0.68 2.0 + 0.68 NS
Post-Activity Level 2.1 + 0.70 2.2 + 0.67 NS
Pre-TDD (U/kg) 0.82 ± 0.20 0.91 ± 0.26 NS
Post- TDD (U/kg) 0.84 ± 0.20 0.87 ± 0.22 NS
Pre % Basal 43.9 ± 12.6 44.1 ± 10.9 NS
Post % Basal 39.1 ± 8.9 41.7 ± 9.2 NS
Pre-bolus:basal 1.49 ± 0.82 1.43 ± 0.70 NS
Post-bolus:basal 1.69 ± 0.65 1.53 ± 0.65 NS
Pre- HbA1c 8.1 ± 0.8 8.2 ± 0.8 NS
Post- HbA1c 7.6 ± 0.6† 7.8 ± 0.7† <0.01
Pre-FBG 179.8 ± 39.9 183.2 ± 48.8 NS
Post-FBG 162.5 ± 33.7† 163.4 ± 31.7 <0.05
Pre-hypo/2 week 1.48 ± 0.75 1.99 ± 0.86 <0.01
Post-hypo/2 week 1.0 ± 0.4† 1.53 ± 0.90† <0.01
Data are mean ± SD. total daily dose (TDD), fasting blood glucose (FBG). Pre”
values represent baseline data collected at the beginning of the study per
group. “Post” values represent data collected after one year of insulin
pump therapy
p- value, comparison between male vs. female
†p < 0.01, Comparison between pre and post characteristics
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